{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T16:34:37Z","timestamp":1788021277914,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00432-020-03430-4","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T18:02:48Z","timestamp":1604340168000},"page":"1481-1491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety"],"prefix":"10.1007","volume":"147","author":[{"name":"For the German Study Group MPN, GSG-MPN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Schrickel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvis","family":"Sadjadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kolatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"3430_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1136\/bmj.320.7251.1708","volume":"320","author":"A-MN Andersen","year":"2000","unstructured":"Andersen A-MN (2000) Maternal age and fetal loss: population based register linkage study. BMJ 320:1708\u20131712. https:\/\/doi.org\/10.1136\/bmj.320.7251.1708","journal-title":"BMJ"},{"key":"3430_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European leukemiaNet. J Clin Oncol 29:761\u2013770. https:\/\/doi.org\/10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol"},{"key":"3430_CR3","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A et al (2012) Development and validation of an international prognostic score of thrombosis in world health organization\u2013essential thrombocythemia (IPSET-thrombosis). Blood 120:5128\u20135133. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"key":"3430_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"key":"3430_CR5","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","volume":"101","author":"Y Beauverd","year":"2016","unstructured":"Beauverd Y, Radia D, Cargo C et al (2016) Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. Case Series Haematol 101:e182\u2013e184. https:\/\/doi.org\/10.3324\/haematol.2015.139691","journal-title":"Case Series Haematol"},{"key":"3430_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1479-828X.2000.tb03163.x","volume":"40","author":"R Cincotta","year":"2000","unstructured":"Cincotta R, Higgins JR, Tippett C et al (2000) Management of essential thrombocythaemia during pregnancy. Aust N Z J Obstet Gynaecol 40:33\u201337. https:\/\/doi.org\/10.1111\/j.1479-828X.2000.tb03163.x","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"3430_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1600-0609.2009.01214.x","volume":"82","author":"N Gangat","year":"2009","unstructured":"Gangat N, Wolanskyj AP, Schwager S, Tefferi A (2009) Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol 82:350\u2013353. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01214.x","journal-title":"Eur J Haematol"},{"key":"3430_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/17474086.2018.1506325","volume":"11","author":"M Griesshammer","year":"2018","unstructured":"Griesshammer M, Sadjadian P, Wille K (2018) Contemporary management of patients with BCR-ABL1 -negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol 11:697\u2013706. https:\/\/doi.org\/10.1080\/17474086.2018.1506325","journal-title":"Expert Rev Hematol"},{"key":"3430_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.blre.2008.03.007","volume":"22","author":"M Griesshammer","year":"2008","unstructured":"Griesshammer M, Struve S, Barbui T (2008) Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev 22:235\u2013245. https:\/\/doi.org\/10.1016\/j.blre.2008.03.007","journal-title":"Blood Rev"},{"key":"3430_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1365-2141.2005.05400.x","volume":"129","author":"C Harrison","year":"2005","unstructured":"Harrison C (2005) Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 129:293\u2013306. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05400.x","journal-title":"Br J Haematol"},{"key":"3430_CR11","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/cancers12071954","volume":"12","author":"J How","year":"2020","unstructured":"How J, Hobbs G (2020) Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers 12:1954. https:\/\/doi.org\/10.3390\/cancers12071954","journal-title":"Cancers"},{"key":"3430_CR12","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.ajog.2004.05.001","volume":"191","author":"P Martinelli","year":"2004","unstructured":"Martinelli P, Martinelli V, Agangi A et al (2004) Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol 191:2016\u20132020. https:\/\/doi.org\/10.1016\/j.ajog.2004.05.001","journal-title":"Am J Obstet Gynecol"},{"key":"3430_CR13","doi-asserted-by":"publisher","first-page":"e1912666","DOI":"10.1001\/jamanetworkopen.2019.12666","volume":"2","author":"D Maze","year":"2019","unstructured":"Maze D, Kazi S, Gupta V et al (2019) Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open 2:e1912666. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.12666","journal-title":"JAMA Netw Open"},{"key":"3430_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/ajh.21504","volume":"84","author":"L Melillo","year":"2009","unstructured":"Melillo L, Tieghi A, Candoni A et al (2009) Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. Am J Hematol 84:636\u2013640. https:\/\/doi.org\/10.1002\/ajh.21504","journal-title":"Am J Hematol"},{"key":"3430_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1600-0609.2004.00324.x","volume":"73","author":"R Niittyvuopio","year":"2004","unstructured":"Niittyvuopio R, Juvonen E, Kaaja R et al (2004) Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol 73:431\u2013436. https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00324.x","journal-title":"Eur J Haematol"},{"key":"3430_CR16","first-page":"6","volume":"110","author":"F Passamonti","year":"2007","unstructured":"Passamonti F, Randi ML, Rumi E et al (2007) Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2. Mutation 110:6","journal-title":"Mutation"},{"key":"3430_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ajh.23635","volume":"89","author":"ML Randi","year":"2014","unstructured":"Randi ML, Bertozzi I, Rumi E et al (2014) Pregnancy complications predict thrombotic events in young women with essential thrombocythemia: pregnancies in patients with essential thrombocythemia. Am J Hematol 89:306\u2013309. https:\/\/doi.org\/10.1002\/ajh.23635","journal-title":"Am J Hematol"},{"key":"3430_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bjh.16453","volume":"189","author":"SE Robinson","year":"2020","unstructured":"Robinson SE, Harrison CN (2020) How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. Br J Haematol 189:625\u2013634. https:\/\/doi.org\/10.1111\/bjh.16453","journal-title":"Br J Haematol"},{"key":"3430_CR19","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.3324\/haematol.2015.131458","volume":"100","author":"E Rumi","year":"2015","unstructured":"Rumi E, Bertozzi I, Casetti IC et al (2015) Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica 100:e443\u2013e445. https:\/\/doi.org\/10.3324\/haematol.2015.131458","journal-title":"Haematologica"},{"key":"3430_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger\u00e5s U, Bergqvist D et al (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202\u2013204. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03678.x","journal-title":"J Thromb Haemost"},{"key":"3430_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","volume":"129","author":"L Skeith","year":"2017","unstructured":"Skeith L, Carrier M, Robinson SE et al (2017) Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood 129:934\u2013939. https:\/\/doi.org\/10.1182\/blood-2016-09-728006","journal-title":"Blood"},{"issue":"6","key":"3430_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","volume":"27","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G (2005) Side effects of interferon-\u03b1 therapy. Pharma World Sci 27(6):423","journal-title":"Pharma World Sci"},{"key":"3430_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08956.x","volume":"156","author":"AA Sultan","year":"2012","unstructured":"Sultan AA, West J, Tata LJ et al (2012) Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study: risk of VTE in and around pregnancy. Br J Haematol 156:366\u2013373. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08956.x","journal-title":"Br J Haematol"},{"key":"3430_CR24","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR et al (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124:2507\u20132513. https:\/\/doi.org\/10.1182\/blood-2014-05-579136","journal-title":"Blood"},{"key":"3430_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. https:\/\/doi.org\/10.1182\/blood-2009-03-209262","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-020-03430-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-020-03430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T18:03:24Z","timestamp":1617645804000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-020-03430-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3430"],"URL":"https:\/\/doi.org\/10.1007\/s00432-020-03430-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"10 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F.H.H, A.H. and M.G. revealed their conflict of interests. The other authors declare that they do have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The questionnaire and study protocol for this retrospective study were approved by the Ethics Committee of the Ruhr-Universit\u00e4t Bochum, based in Bad Oeynhausen (Protocol file number #2017\u2013285)<i>.<\/i>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients gave informed consent regarding publication of their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}